Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Spinocerebellar ataxia type 10 Indication Strategy Report 2026: ATXN10, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 10 strategy: epidemiology, ATXN10 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 2 Indication Strategy Report 2026: ATXN2, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 2 strategy: epidemiology, ATXN2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
SAPHO syndrome Indication Strategy Report 2026: IL-17A, Trials and Deals
24 July 2026
2026 SAPHO syndrome strategy: epidemiology, IL-17A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Rasmussen encephalitis Indication Strategy Report 2026: IL-6, Trials and Deals
24 July 2026
2026 Rasmussen encephalitis strategy: epidemiology, IL-6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Febrile infection-related epilepsy syndrome Indication Strategy Report 2026: IL-1 receptor, Trials and Deals
24 July 2026
2026 Febrile infection-related epilepsy syndrome strategy: epidemiology, IL-1 receptor biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Juvenile dermatomyositis Indication Strategy Report 2026: IFNAR1, Trials and Deals
24 July 2026
2026 Juvenile dermatomyositis strategy: epidemiology, IFNAR1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pemphigus foliaceus Indication Strategy Report 2026: DSG1, Trials and Deals
24 July 2026
2026 Pemphigus foliaceus strategy: epidemiology, DSG1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Immune-mediated necrotizing myopathy Indication Strategy Report 2026: FcRn, Trials and Deals
24 July 2026
2026 Immune-mediated necrotizing myopathy strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Linear IgA bullous dermatosis Indication Strategy Report 2026: FcRn, Trials and Deals
24 July 2026
2026 Linear IgA bullous dermatosis strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Dissecting cellulitis of the scalp Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Dissecting cellulitis of the scalp strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Epidermolysis bullosa acquisita Indication Strategy Report 2026: COL7A1, Trials and Deals
24 July 2026
2026 Epidermolysis bullosa acquisita strategy: epidemiology, COL7A1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Central centrifugal cicatricial alopecia Indication Strategy Report 2026: PPAR-gamma, Trials and Deals
24 July 2026
2026 Central centrifugal cicatricial alopecia strategy: epidemiology, PPAR-gamma biology, clinical competition, recent deals, unmet need and market attractiveness.